Pulmonary Vein Stenosis Program Research and Innovation

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Pulmonary Vein Stenosis Program

Our Pulmonary Vein Stenosis team bases treatment on the latest clinical research. At Boston Children’s, we have one of the world’s most extensive research programs and our scientists work directly with our doctors so that the newest treatments are always available.

Historically, doctors have had to rely on one of the following treatments to care for children with pulmonary vein stenosis:

  • open-heart surgery to widen the narrowed veins and improve blood flow from the lungs back to the heart

  • cardiac catheterization with balloon dilation to try to stretch the vessel(s) open

  • lung transplantation to replace the lungs and the pulmonary veins

Response to surgery or catheterization is usually short-lived. Typically, within three to four weeks, the obstruction recurs, and repeating surgery only provides temporary fixes.

In some cases, lung transplantation may be an option, but this comes with major risks, including rejection of the transplanted lung and serious infection. Patients must also take immunosuppressant drugs for the remainder of his or her life to help reduce the chance of the body rejecting the new lungs.

Using these methods, many children with the most severe form of pulmonary vein stenosis do not survive past early childhood.

Innovative solution

The Dana-Farber Cancer Institute and Boston Children's Hospital are conducting a research study in patients who have multi-vessel (greater than two vessels) pulmonary vein stenosis. The purpose of this study is to determine the effectiveness of using two standard chemotherapy drugs that target myofibroblasts in pulmonary veins and control the abnormal growth of these cells.

The study involves treatment with Avastin and Gleevec, two medications used to safely treat childhood tumors. Multi-vessel intraluminal pulmonary vein stenosis is not thought to be a tumor, but it does share a common feature with tumors: the unwanted growth of cells.

Gleevec is given daily by mouth, while Avastin is given intravenously once every two weeks. They both have low side-effects and have been well tolerated in infants, children and adults. The goal of treatment is to stabilize the unwanted cell growth to improve patients’ life expectancy and quality of life. The trial involves treatment for one year, and can be coordinated close to a patient's home area.

Current Research

In order for your child to qualify for the study they must have: 

  • Evidence of intraluminal pulmonary vein stenosis in > 1 vessel

  • Acceptable organ function

  • Evidence of myofibroblast neo-proliferation, if biopsies were obtained

After initial contact, we will need the following information in order to help determine whether or not your child qualifies for the current study:

  • Current patient status

  • Clinic notes

  • Surgery documentation

  • Echo CD's and reports

  • Catheterization CD's and reports

  • CT scan CD's and reports

  • Recent lung scans

  • Insurance information

Please have CD's mailed to:
Attn: PVS team
Boston Children's Hospital
Cardiology—Device Group
300 Longwood Ave
Boston, MA 02115

  • Please fax clinical documents to 617-919-3007 Attn: PVS team.

  • Feel free to contact us at pvs@cardio.chboston.org or call 617-919-3430 with any additional questions.

  • Please include your contact information so that we can follow up upon receipt and review of your child's information

  • You can also schedule an outpatient appointment by calling 617-355-6000.

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close